Oxysterols and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11732000-B2
Application number	US-202117396034-A
Country	US
Kind code	B2
Filing date	Aug 6, 2021
Priority date	Jul 6, 2015
Publication date	Aug 22, 2023
Grant date	Aug 22, 2023

Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , and R 3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

2. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is:

4. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

5. The compound of claim 1 , wherein the compound is:

6. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

7. The compound of claim 1 , wherein the compound is:

8. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

9. The compound of claim 1 , wherein the compound is:

10. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

11. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of any one of claim 2 , 4 , 6 , 8 or 10 and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising a compound of any one of claim 1 , 3 , 5 , 7 , or 9 and a pharmaceutically acceptable carrier.

Assignees

• Sage Therapeutics Inc

Inventors

• Salituro Francesco G
• Robichaud Albert Jean
• Martinez Botella Gabriel
• Harrison Boyd L

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title